Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Completed
Chinese University of Hong Kong
Phase 3
2005-06-01
The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus
a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a
history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients
with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole
would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer
bleeding.
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
Terminated
Novacea
Phase 2
2005-03-01
To determine whether, in this patient population, treatment with calcitriol and Naproxen is
more effective in delaying the growth of prostate cancer than treatment with calcitriol alone
as seen in historical controls.
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
Terminated
Stanford University
Phase 2
2005-03-01
To determine whether, in this patient population, treatment with calcitriol and Naproxen is
more effective in delaying the growth of prostate cancer than treatment with calcitriol alone
as seen in historical controls.
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Completed
POZEN
Phase 3
2007-09-01
This study uses a randomized, double-blind, controlled design to demonstrate that PN400
(esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal
ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric
ulcers compared to naproxen alone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
